Spooked by US president's threat, several Indian pharma players lobby for blanket duty waiver on drugs coming from America, ...

The sector is already on a growth trajectory, with exports reaching $27.9 billion in the fiscal year 2023-24 (April ...

India’s Contract Development and Manufacturing Organization (CDMO) market is witnessing a strong growth trajectory driven by ...

A study linking Indian generic drugs to a higher risk of serious side effects in the US has spurred backlash from the Indian ...

Former Pharmexcil Director-General warns India against reducing import duties under US pressure, citing potential industry ...

American biggies are joining hands with Chinese companies. AbbVie signed a deal with Simcere Zaiming for a multiple myeloma ...

The development is set to make India less reliant on China for imports of raw material used by the pharmaceutical industry.

The US relies heavily on Indian generic medicines, with nearly half of all generic drugs consumed in the US originating from ...

The Indian Pharmaceutical Alliance (IPA) has proposed reducing the import duty on pharma products from the US to zero.

Indian pharmaceutical CDMOs are anticipated to encounter minimal disruptions from the proposed US tariffs of 10-25 per cent.

Introduction of a direct-to-patient delivery model for its weight-loss drug in the United States could potentially delay its ...